• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nanox to Report Fourth Quarter 2022 Financial Results on March 9, 2023

    2/23/23 9:00:00 AM ET
    $NNOX
    Medical Electronics
    Health Care
    Get the next $NNOX alert in real time by email

    NANO-X IMAGING LTD ((", Nanox", or the ", Company, ", NASDAQ:NNOX) will report its financial results for the fourth quarter ended December 31, 2022 before market on Thursday, March 9, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET.

    Interested parties may register for the conference call using the following link: Nanox Q4 2022 Earnings Registration Link. You may access the live webcast of the conference call by using the following link: Nanox Q4 2022 Earnings. The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations.

    About Nanox:

    Nanox (NASDAQ:NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. The vision of Nanox is to increase the early detection of medical conditions that are discoverable by medical image technologies based on X-rays, which Nanox believes is key to increasing early prevention and treatment, improving health outcomes, and, ultimately, saving lives. Nanox is developing a holistic imaging solution, which includes the Nanox System, comprised of the Nanox.ARC using its novel MEMs X-ray source technology, and the Nanox.CLOUD, a companion cloud software, integrated with AI solutions and teleradiology services. For more information, please visit www.nanox.vision.

    Forward-Looking Statements:

    This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company's research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as "can," "might," "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "should," "could," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox's ability to complete development of the Nanox System; (ii) Nanox's ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox's expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox's ability to realize the anticipated benefits of the recent acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox's ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (vii) Nanox's expectations regarding collaborations with third-parties and their potential benefits; and (viii) Nanox's ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; and (x) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things.

    For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox's actual results to differ from those contained in the Forward-Looking Statements, see the section titled "Risk Factors" in Nanox's Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release.

    Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this report to conform these statements to actual results or to changes in the Company's expectations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005024/en/

    Get the next $NNOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NNOX

    DatePrice TargetRatingAnalyst
    1/6/2025$23.00Buy
    D. Boral Capital
    9/8/2023$14.50Buy
    Alliance Global Partners
    1/5/2023$21.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $NNOX
    Leadership Updates

    Live Leadership Updates

    See more
    • Nanox Announces Appointment of Medical Executive Moshe Shtengel as Chief Business Officer

      NEVE ILAN, Israel, May 03, 2021 (GLOBE NEWSWIRE) -- NANOX IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, announced today the appointment of Moshe Shtengel as Chief Business Officer, effective May 2, 2021. Mr. Shtengel joins Nanox from Tuttnauer, a global manufacturer of sterilizers and infection control systems for medical institutions, where he served as Vice President of Global Sales, Marketing and Products. "Moshe is an extremely seasoned sales and business development executive with a proven track record of success and leadership in the medical field," stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. "As we

      5/3/21 8:00:00 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nanox to Report First Quarter 2025 Financial Results on May 22, 2025

      PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be

      5/8/25 4:03:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X

      First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indicationsEnhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play' installation processSystem design enables software upgrades and new capabilities to be added remotely following future regulatory clearances PETACH TIKVA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Nanox.ARC X

      4/17/25 8:30:54 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox to Present New Data Featuring AI Bone Solution at Four Medical Conferences through June 2025 across Europe

      ADOPT Study Findings Highlight Nanox.AI's Role in Enhancing Fracture Detection and Healthcare Cost Savings PETACH TIKVA, Israel, March 26, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox AI Ltd will present new data from the AI-enabled Detection of OsteoPorosis for Treatment (ADOPT) study at four major upcoming medical conferences spanning March through June 2025. The ADOPT study concluded in February 2025 and evaluated HealthVCF at four National Health Services (NHS) trusts: Cambridge, Bradford, Cardiff and

      3/26/25 7:00:13 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Financials

    Live finance-specific insights

    See more
    • Nanox to Report First Quarter 2025 Financial Results on May 22, 2025

      PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, 2025, before market open on Thursday, May 22, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q1 2025 Earnings Call Registration. The live webcast of the conference call may be

      5/8/25 4:03:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      PETACH TIKVA, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ((", Nanox", or the ", Company", , NASDAQ:NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2024, before market open on Monday, March 31, 2025. Erez Meltzer, Chief Executive Officer and Acting Chairman, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. The live webcast of the conferenc

      3/17/25 4:05:00 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update

      Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ:NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update. Recent Highlights: Generated $3.0 million in revenue in the third quarter of 2024, compared to $2.5 million in the third quarter of 2023

      11/21/24 8:00:00 AM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    SEC Filings

    See more

    $NNOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form 6-K filed by NANO-X IMAGING LTD

      6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

      4/17/25 8:40:02 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form 20-F filed by NANO-X IMAGING LTD

      20-F - Nano-X Imaging Ltd. (0001795251) (Filer)

      4/9/25 4:29:36 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by NANO-X IMAGING LTD

      6-K - Nano-X Imaging Ltd. (0001795251) (Filer)

      3/31/25 8:37:25 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

      SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

      3/7/24 12:29:51 PM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G filed by NANO-X IMAGING LTD

      SC 13G - Nano-X Imaging Ltd. (0001795251) (Subject)

      2/6/24 9:36:34 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • SEC Form SC 13G/A filed by NANO-X IMAGING LTD (Amendment)

      SC 13G/A - Nano-X Imaging Ltd. (0001795251) (Subject)

      2/14/23 4:15:16 PM ET
      $NNOX
      Medical Electronics
      Health Care

    $NNOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Nano-X Imaging with a new price target

      D. Boral Capital initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $23.00

      1/6/25 9:02:00 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Alliance Global Partners initiated coverage on Nano-X Imaging with a new price target

      Alliance Global Partners initiated coverage of Nano-X Imaging with a rating of Buy and set a new price target of $14.50

      9/8/23 9:14:06 AM ET
      $NNOX
      Medical Electronics
      Health Care
    • Cantor Fitzgerald initiated coverage on Nano-X Imaging with a new price target

      Cantor Fitzgerald initiated coverage of Nano-X Imaging with a rating of Overweight and set a new price target of $21.00

      1/5/23 7:46:34 AM ET
      $NNOX
      Medical Electronics
      Health Care